Pacifor® Oral Solution

Oral solution.

Tranquilizer.

Each 100 mL of oral solution contains:
Acepromazine Maleate…………… 1.35 g
(Equivalent to 1 g of Acepromazine base)
Excipients c.s.p………………….100 mL

Pacifor® Oral solution, it is indicated as a sedative agent (tranquilizer) for dogs and cats.

Oral.

• Dogs: 1 to 2 drops per Kg of body weight (0.5 to 1 mg/Kg).
• Cats: 2 to 3 drops per Kg of body weight (1 to 1.5 mg/Kg).

The calming effect takes about 30 to 40 minutes. Place the animal in a quiet environment. The duration of the effect is 6 to 12 hours.

Dogs and cats.

• Do not administer to pregnant or lactating females.
• Do not use in animals undergoing examinations such as myelograms.
• Do not use in animals with a history of seizures.
• Do not administer to animals with hypovolemia or shock, due to its hypotensive effects.
• Do not administer to animals with coagulopathies or thrombocytopenia, due to its effects on platelet aggregation.
• Do not administer to animals with tetanus or strychnine poisoning, due to its effects on the extrapyramidal system.
• Do not administer within one month of deworming with organophosphate agents, as their effects may be enhanced.

• Acepromazine causes vasodilation-mediated hypotension, which can last for several hours and should be considered during its use. In healthy animals, this hypotension is usually mild; however, it can be accentuated in anesthetized, debilitated, or hypovolemic patients.
• Unusual cardiovascular collapse of varying severity (secondary to bradycardia and hypotension) has been reported in some dogs, especially in brachycephalic breeds.
• Acepromazine causes significant intraoperative hypothermia because it depresses the hypothalamic thermoregulatory center and causes cutaneous vasodilation. This effect lasts for several hours.
• Acepromazine causes prolapse of the nictitating membrane, which lasts for several hours while its effect is maintained.
• Acepromazine can decrease the hematocrit for several hours as a result of splenic congestion after α1-adrenergic receptor blockade, which can be significant in anemic animals. This effect is transient and is restored after several hours.
• Acepromazine temporarily decreases platelet aggregation without affecting clotting times.
  Occasionally, acepromazine may produce contradictory clinical signs of aggression and generalized stimulation of the central nervous system. These reactions are rare and transient, and generally do not last more than 48 hours

• After administration of Acepromazine, lower doses of general anesthetics are required.
• Use with caution and at the lowest recommended dose in animals with hepatic dysfunction, heart disease, and general weakness.
• Use with caution in very young or debilitated animals, due to its effects on thermoregulation.
• Use with caution in geriatric patients, as very low doses have been associated with prolonged effects of the drug.
• Acepromazine does not possess analgesic effects, so appropriate measures should be taken to control pain in treated animals.
• Use with caution in brachycephalic dogs (Boxers, Pekingese, etc.) or Persian cats, as they may be very sensitive to the bradycardic effects of Acepromazine.
• Use with caution in dogs with MDR1 mutations (Collies, Australian Shepherds, among others), as they may develop deeper sedation that persists longer than usual.
• Giant breeds and Greyhounds can be extremely sensitive to the drug, while terrier breeds are somewhat resistant to its effects.
• Acepromazine should be used with caution as a containment agent in aggressive dogs, as it may cause animals to be more prone to startle and react to noises or other sensory stimuli.
• Atropine can be used in conjunction with Acepromazine to help block its bradycardic effects.
• During sedation with Acepromazine it is recommended to use ocular lubricants or artificial tears as corneal protectors, due to the reduction in tear production.
• A higher dose does not accelerate the onset of sedation, it only lengthens the sedative effect.
• Once it has been administered, it is important to leave the animal in a quiet place for about 15 minutes or until the sedative effects are achieved.
• After administration, patients should not be exposed to extreme temperature fluctuations for at least 8 hours.
• Administration in conjunction with other respiratory or central nervous system depressants may exacerbate respiratory depression.
• Keep out of reach of children and pets.

• Combinations of antidiarrheals (e.g., kaolin-pectin, mixtures with bismuth subsalicylate) and antacids may reduce gastrointestinal absorption of orally administered phenothiazines.
• Central Nervous System (CNS) depressant agents (barbiturates, narcotics, anesthetics, etc.), may exacerbate CNS depression if used in conjunction with acepromazine.
• Epinephrine: Phenothiazines block alpha-adrenergic receptors; concomitant administration with epinephrine may lead to beta activity causing vasodilation and increased heart rate.
• Opioids: May improve the hypotensive effects of Acepromazine. Doses of Acepromazine are usually reduced when used with an opioid.
• Organophosphate agents: Acepromazine should not be administered within one month of deworming with these agents as their effects may be potentiated.
• Phenytoin: Its metabolism may decrease if given simultaneously with phenothiazines.
• Procaine: Activity can be enhanced by phenothiazines.
• Propranolol: Co-administration of acepromazine and propanolol may lead to serum elevation of both drugs.
• Quinidine: With phenothiazines it can cause additive cardiac depression.
• Vasoconstrictors, such as phenylephrine, antagonize the hypotensive effects of phenothiazines.

In case of contact with skin, eyes, or mucous membranes, rinse immediately with plenty of water. If irritation occurs, seek medical attention and show the product information leaflet. In case of accidental ingestion, seek medical attention immediately and show the product information leaflet.

Dispose of this product carefully with household waste. Do not dispose of empty containers with product residue on the ground or in waterways. For expired or unused products, contact the manufacturer.

Store at room temperature below 25 °C. Do not refrigerate or freeze. Once opened, use within 12 weeks. Discard unused product after this period. For export: Store in a cool, dry place at room temperature between 15 and 30 °C.

Sale by prescription to the Veterinary Doctor.
Peru: Under prescription restricted.

Chile: Reg. SAG N° 516
Bolivia: Reg. SENASAG PUV-F-N° 005517/13
Peru: Reg. SENASA F.62.32.I.0026

Bottle with 10 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.